Please wait while we load the requested 10-Q report or click the link below:
FOR IMMEDIATE RELEASE
VP, Investor Relations
Glaukos Corporation Announces Second Quarter 2017 Financial Results
San Clemente, CA – August 2, 2017 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the second quarter ended June 30, 2017. Key highlights include:
“These results represent another quarter of record performance for Glaukos shareholders and reflect the continued successful execution of our growth strategy,” said Thomas Burns, Glaukos president and chief executive officer. “We remain fully focused on increasing global adoption of our iStent® and iStent inject® Trabecular Micro Bypass Stents by growing the ranks of trained surgeons, helping them integrate the technology into their practices, and expanding the body of compelling clinical evidence that underscores the benefits of our micro-scale glaucoma technology to patients, practitioners and payors. In addition, we continue to advance our industry-leading pipeline of micro-scale innovations designed to transform glaucoma therapy.”
Second Quarter 2017 Financial Results
Net sales rose 45% in the second quarter of 2017 to $41.3 million, compared to $28.6 million in the same period in 2016. The growth reflected strong global unit volume increases, higher average selling prices and expansion of the company’s direct sales operations into new international markets.
Gross margin for the second quarter of 2017 was approximately 87%, compared to 85% in the same period in 2016.
The following information was filed by Glaukos Corp (GKOS) on Wednesday, August 2, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Glaukos Corp's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Glaukos Corp.